Volume 29, Issue 6, June 2024

This study investigated the incidence and the characteristics of dermatological adverse events related to ribociclib and their impact on safety and efficacy of the treatment.

The impact of the co-administration of proton pump inhibitors with cyclin-dependent kinase 4 and 6 inhibitors remains controversial. This study clarified whether the concomitant use of proton pump inhibitors impacts the effectiveness of palbociclib and abemaciclib in patients with breast cancer.

This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological Centers in the Czech Republic, and indirectly compared these findings with international data.

This study assessed the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer.

Methylthioadenosine phosphorylase (MTAP)-loss is a developing drug target through synthetic lethality with MAT2A and PMRT5 inhibitors. This study investigated the prevalence and genomic landscape of MTAP-loss in advanced gastrointestinal tumors and its role as a prognostic biomarker.

This study investigated the clinical outcomes of patients affected by cancers of unknown primary in a real-world context and examined whether comprehensive genomic profiling might provide clinical utility by addressing biomarker identification to possibly adapt personalized and targeted treatment strategies.

In CheckMate 214, improved overall survival (OS) and better health-related quality of life (HRQoL) were observed with nivolumab plus ipilimumab versus sunitinib in patients with previously untreated immediate-risk or poor-risk advanced renal cell carcinoma. This study analyzed 5-year follow-up data to determine whether HRQoL scores can predict the OS.

This article reports a prognostic model that was developed to predict survival in older patients with transplant-ineligible multiple myeloma and may improve communication regarding prognosis and shared decision-making.

The poor prognosis of breast cancer in Sudan could be due to delayed treatment and diagnosis at an advanced stage. This article assesses the extent of delays from onset of symptoms to treatment in Sudanese women with breast cancer and identifies factors contributing to these delays.

HPV-associated malignancies account for ~5% of human cancers worldwide. This article summarizes what we know about these cancers and proposes future directions to guide treatment for affected patients.

Larotrectinib is a first-in-class, highly selective, central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. This article reports the efficacy and safety of larotrectinib in patients with TRK fusion-positive salivary gland cancers.

In precision oncology, tumor-agnostic therapies target genomic alterations irrespective of tumor location; however, traditional value frameworks and approval pathways can limit patient access to such therapies. This article describes challenges and possible solutions to improve patient access.

This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medicaid-insured patients received high-priced treatments in similar proportion overall, but commercially insured patients were more likely to receive high-priced treatments in community practice settings.

This article presents a single-center experience with the Berlin-Frankfurt-Münster protocol, with the addition of rituximab, followed by autologous stem cell transplantation, when feasible, in adult patients with Burkitt lymphoma.

This article evaluates the clinical outcomes of etoposide and cytarabine consolidation chemotherapy following high-dose methotrexate-based induction chemotherapy in transplant-ineligible patients aged >60 years with primary central nervous system lymphoma.

Accurate prognostic stratification of hepatocellular carcinoma (HCC) is vital for clinical trial enrollment and treatment allocation. This article reports a scoring system for HCC that incorporates standardized radiologic tumor features and more accurately predicts overall survival than established systems.

This review outlines how the innovative use of single-cell technologies to study the normal and malignant biology of the thymus has transformed our understanding of thymic epithelial tumors.

This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with advanced non-small cell lung cancer with an actionable driver oncogene in a predominately community setting.

This article provides an overview of the molecular landscape of malignant melanoma in patients who underwent next-generation sequencing at a single tertiary institution in South Korea, and presents results from a belvarafenib Expanded Access Program (EAP).

This study investigated the efficacy and toxicity after long-term follow-up of anti-PD-1 antibodies in advanced melanoma with predominantly acral and mucosal subtypes.

This case report describes a patient with advanced oligometastatic non–small cell lung cancer with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.

The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (primary/secondary), and impact of hypogonadism on quality of life in male patients with cancer on antineoplastic therapy.

This study aimed to determine the feasibility and preliminary efficacy of an exercise intervention based on a patient-preferred delivery mode in patients affected by metastatic cancer.

This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing.

For cancer clinical trials that require confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. This article describes a process to repurpose existing commercial vendor raw genomic data for eligibility.